LON:ROQ Roquefort Therapeutics (ROQ) Share Forecast, Price & News GBX 6.75 0.00 (0.00%) (As of 05/25/2023) Add Compare Share Share Today's Range 6.75▼ 6.7550-Day Range 6.55▼ 7.4252-Week Range 6.08▼ 11.75VolumeN/AAverage Volume208,173 shsMarket Capitalization£8.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Roquefort Therapeutics (LON:ROQ) StockRoquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Stock News HeadlinesMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"May 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 6, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardFebruary 22, 2023 | lse.co.ukRoquefort Thera Regulatory NewsFebruary 21, 2023 | barrons.comRoquefort Therapeutics PLCFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks Randox diagnostic dealMay 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.February 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxJanuary 26, 2023 | finance.yahoo.comRoquefort Therapeutics demonstrates initial safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics demonstrates safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics cancer drugs enjoy pre-clinical successJanuary 9, 2023 | proactiveinvestors.comRoquefort Therapeutics CEO lays out strategy for 2023January 9, 2023 | proactiveinvestors.comRoquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companiesOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics to present breakthrough RNA cancer study results at key conferenceOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics explains the significance of its "very exciting" cancer drug study resultsSeptember 21, 2022 | msn.comStratford-upon-Avon company bought in multi-million pound dealSeptember 20, 2022 | msn.comBiotech firm Oncogeni acquired in £5.5m dealSeptember 17, 2022 | morningstar.comUK Retailers Drop After August Sales SlumpSeptember 16, 2022 | thetimes.co.ukRoquefort enlists Nobel prizewinner Sir Martin EvansSeptember 16, 2022 | proactiveinvestors.comFTSE 100 opens lower as world bank warns of recession.September 2, 2022 | uk.finance.yahoo.comRoquefort Therapeutics plc (ROQ.L)August 20, 2022 | investing.comRoquefort Investments PLC (ROQ)July 15, 2022 | finance.yahoo.comRoquefort Therapeutics PLC Announces Commencement of Trading on US OTCQB Venture MarketSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ROQ CUSIPN/A CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.13 Quick Ratio3.07 Sales & Book Value Annual Sales£637.00 Price / Sales13,685.44 Cash FlowGBX 4.52 per share Price / Cash Flow1.49 Book ValueGBX 5 per share Price / Book1.35Miscellaneous Outstanding Shares129,150,000Free FloatN/AMarket Cap£8.72 million OptionableNot Optionable Beta-0.04 Key ExecutivesMr. Stephen Paul West B.Com (Age 49)CA, Exec. Chairman Mr. Trevor Ajanthan ReginaldCEO & Exec. DirectorProf. Martin J. Evans FRSGroup Chief Scientific Officer & Exec. DirectorDr. Armand Keating M.D.Independent Chief Medical OfficerKey CompetitorsRUA Life SciencesLON:RUACizzle BiotechnologyLON:CIZOptiBiotix HealthLON:OPTIBiVictriX TherapeuticsLON:BVXIXICOLON:IXIView All CompetitorsInsidersDr Darrin DisleyBought 515,913 shares on 9/26/2022Total: £4.13 M ($8.00/share)Stephen Paul WestBought 210,000 shares on 7/4/2022Total: £1.89 M ($9.00/share)Stephen Paul WestBought 55,147 shares on 6/30/2022Total: £496,323.00 ($9.00/share)View All Insider Transactions ROQ Stock - Frequently Asked Questions How have ROQ shares performed in 2023? Roquefort Therapeutics' stock was trading at GBX 6.75 at the beginning of 2023. Since then, ROQ stock has increased by 0.0% and is now trading at GBX 6.75. View the best growth stocks for 2023 here. What is Roquefort Therapeutics' stock symbol? Roquefort Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ROQ." How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Roquefort Therapeutics' stock price today? One share of ROQ stock can currently be purchased for approximately GBX 6.75. How much money does Roquefort Therapeutics make? Roquefort Therapeutics (LON:ROQ) has a market capitalization of £8.72 million and generates £637.00 in revenue each year. The company earns £-1,150,000.00 in net income (profit) each year or GBX (2.80) on an earnings per share basis. How can I contact Roquefort Therapeutics? The official website for the company is www.roquefortinvest.com. The company can be reached via phone at 44 20 3290 9339. This page (LON:ROQ) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.